{"paper_id":"c342e9d6-870c-4bb2-b2b2-3a62eeea2f44","body_text":"Case Reports\nBenign, Borderline, and Malignant Endometrioid Neoplasia Arising in Endometriosis in Association with Tamoxifen Therapy\n- W. G. McCluggage\n- C. Bryson\n- H. Lamki\n- D. D. Boyle\nInternational Journal of Gynecological Pathology 19(3):p 276-279, July 2000.\nSummary:\nTamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenocarcinoma, and as recently suggested, proliferative changes within endometriosis. This report describes an endometrioid adenocarcinoma arising in ovarian endometriosis in a patient taking tamoxifen. There were also foci of benign and borderline endometrioid adenofibroma in the same ovary and a synchronous endometrioid endometrial adenocarcinoma in the uterus. The spectrum of benign, borderline, and malignant endometrioid neoplasia arising within endometriosis suggests that tamoxifen, as a result of its estrogenic effects, may cause proliferative and, in rare instances, malignant changes in endometriosis.\nCopyright © 2000 Lippincott Williams & Wilkins, Inc.","source_license":"CC0","license_restricted":false}